Soleno reports death of VYKAT XR patient; company says not drug-related

SOLENO THERAPEUTICS INC

A 17-year-old male with lymphedema, thrombophlebitis, and obesity died from pulmonary embolus; FAERS report filed.
Treating physician and Soleno assessed the death as not related to VYKAT XR treatment.
Soleno reaffirms VYKAT XR safety profile and urges use per FDA-approved label.
Company will not comment on future adverse events unless directly linked to VYKAT XR and unexpected per label.
Prader Willi Syndrome patients have reduced life expectancy; mean age of death is 29.5 years per 40-year study.

item 7.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.